Nanotech Company and US Defense Department Join Forces To Treat Dengue Fever
Connecticut-based NanoViricides Inc. announced this month it has entered into a joint R&D agreement with the Walter Reed Army Institute of Research that will focus on developing a drug to treat dengue fever. Dengue fever is a mosquito-borne, flu-like illness that can last as long as a month and in some severe cases, be fatal. As part of the agreement, NanoViricides will develop the drugs, and the Institute will test them. NanoViricides is a company that creates nanomaterials for viral therapy.